Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xiu-Zhi Zhu
Observed names:
X Zhu,
X. Zhu,
Xiuzhi Zhu,
Zhu, Xiuzhi
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
Observed institutions:
Northwell Health,
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Gannan Medical University
ORCID:
0000-0001-5564-1719
Observed ORCID:
0000-0001-5564-1719
OpenAlex ID:
A5109786272
Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
2021
·
Xiuzhi Zhu
, Li Chen
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
114
PDF
Single-cell morphological and topological atlas reveals the ecosystem diversity of human breast cancer
2023
·
Shen Zhao
, De-Pin Chen
, et al.
·
Nature Communications
·
93
PDF
Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial
2023
·
Yin Liu
, Xiu-Zhi Zhu
, et al.
·
Cell Research
·
86
PDF
Risk and prognostic factors of breast cancer with liver metastases
2021
·
Lei Ji
, Lei Cheng
, et al.
·
BMC Cancer
·
79
PDF
High Expression of microRNA-223 Indicates a Good Prognosis in Triple-Negative Breast Cancer
2021
·
Li Chen
, Xiuzhi Zhu
, et al.
·
Frontiers in Oncology
·
20
PDF
A Prognostic Model for Breast Cancer With Liver Metastasis
2020
·
Lei Ji
, Lei Fan
, et al.
·
Frontiers in Oncology
·
13
PDF
Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
·
Cancer Research
·
11
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2− breast cancer: The LINUXtrial
2025
·
Lei Fan
, Wen-Juan Zhang
, et al.
·
Cancer Cell
·
9
Prognostic Score for De Novo Metastatic Breast Cancer With Liver Metastasis and Its Predictive Value of Locoregional Treatment Benefit
2021
·
Lei Ji
, Lei Fan
, et al.
·
Frontiers in Oncology
·
8
Switching from messenger RNAs to noncoding RNAs, METTL3 is a novel colorectal cancer diagnosis and treatment target
2025
·
Jun-Nan Liao
, Wen-Juan Ni
, et al.
·
World Journal of Gastrointestinal Oncology
·
7
Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets
2026
·
Kun-Yu Zhang
, Xiu-Zhi Zhu
, et al.
·
Signal Transduction and Targeted Therapy
·
6
PDF
Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial)
2025
·
Xi-Yu Liu
, Xin-Yi Sui
, et al.
·
Molecular Cancer
·
4
Oesophagectomy following noncurative endoscopic resection for oesophageal carcinoma: does interval matter?
2022
·
Binhao Huang
, Yangqing Deng
, et al.
·
European Journal of Cardio-Thoracic Surgery
·
3
Research progress on N6-methyladenosine RNA modification in osteosarcoma: functions, mechanisms, and potential clinical applications
2025
·
Ying Yang
, Wen-Juan Ni
, et al.
·
Medical Oncology
·
2
Abstract PO1-15-07: Subtyping-directed precision treatment refines traditional one-size-fits-all therapy in HR+/HER2- breast cancer: a sub-study of the MULAN umbrella trial
2024
·
Xiu-Zhi Zhu
, Xi Jin
, et al.
·
Cancer Research
·
2
[Multivariate analysis for prognostic predictors in non-small cell lung cancer].
2001
·
X Fu
, G Jiang
, et al.
·
PubMed
·
1
Real-world clinical outcomes of trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer
2026
·
Kun-Yu Zhang
, Xiu-Zhi Zhu
, et al.
·
BMC Cancer
Table S6 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S1 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S4 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Data from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Show more works
View as search
Works count:
41
Citation count:
458
H-index:
8
I10-index:
7
Year
Topic
Type